RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of

Status Terminated

Clinical Trial Summary

The purpose of the study was to test a null hypothesis that a combined modality treatment of esophageal cancer with neoadjuvant chemotherapy or chemoradiotherapy is equivalent to surgery alone and what are the benefits from adding irradiation to chemotherapy in neoadjuvant treatment of esophageal cancer.

Clinical Trial Description

The choice of the most beneficial method of treatment in esophageal cancer remains controversial and is the subject of vigorous debate. Surgery is still regarded as the principle modality among treatment strategies, with longterm survival achieved mainly in less advanced cases. More advanced cases, diagnosed more frequently, are more problematic in selection of the optimal therapeutic method. One of the options for improving treatment outcome in patients with advanced esophageal cancer is combined modality treatment with chemo- and chemoradiotherapy. Currently available RCTs have tested preoperative chemotherapy or chemoradiotherapy separately in comparison to surgery alone. Moreover, we do not know from these trials what is the added value of irradiation in a combined modality therapy over a preoperative chemotherapy. Another drawback of available RCTs is combining 2 different biological cancer entities: adenocarcinoma and squamous cell carcinoma of the esophagus as well as carcinoma of the esophagus and gastro-esophageal junction. That were the reasons for designing our trial testing 3 principal modes of esophageal cancer therapy: surgery vs. chemotherapy + surgery vs. chemoradiotherapy + surgery on homogenous population of esophageal cancer patients with single pathological type - squamous cell carcinoma affecting thoracic esophagus. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00559351
Study type	Interventional
Source	Ministry of Scientific Research and Information Technology, Poland
Contact
Status	Terminated
Phase	Phase 3
Start date	December 2001
Completion date	April 2004

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05013697` - TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.	Phase 2
Completed	`NCT02128243` - Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer	Phase 2
Completed	`NCT02253602` - Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer	N/A
Completed	`NCT01900691` - Removal of the Evolution® Esophageal Stent - Fully Covered	N/A
Completed	`NCT01719926` - Phase I Platinum Based Chemotherapy Plus Indomethacin	Phase 1
Terminated	`NCT01572987` - Endoscopic Resection or Ablation for Patients With Dysplasia or Cancer Requiring Treatment of Barrett's Esophagus	N/A
Terminated	`NCT00760604` - A Phase III Study of En Bloc Versus Non-En Bloc Esophagectomy in Esophageal Cancer	Phase 3
Completed	`NCT00160030` - Study Comparing Radiochemotherapy With Folfox 4 Regimen or 5FU-Cisplatin in Patients With Inoperable Esophageal Cancer	Phase 2
Suspended	`NCT00048529` - Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus	Phase 2
Recruiting	`NCT05007106` - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)	Phase 2
Completed	`NCT02284802` - Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy	N/A
Terminated	`NCT03223662` - Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy	Phase 2
Completed	`NCT05680077` - KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Completed	`NCT03549494` - Evaluation of Ocoxin®-Viusid® in Advanced Stomach Cancer and Gastric Esophagogastric Junction	Phase 2
Completed	`NCT03261947` - A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors	Phase 2
Terminated	`NCT00094978` - Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum	Phase 1
Recruiting	`NCT02908204` - Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma	N/A
Completed	`NCT02378948` - Nutritional Route In Esophageal Resection Trial II	N/A
Completed	`NCT02703142` - Endoscopic Evaluation After Esophagectomy	N/A
Recruiting	`NCT02604615` - The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms